Clinical trials: Tumors, Breast
Breast Cancer
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine…
- Trial name
- NCT05496829
- Testing
- Multicomponent Adherence Intervention, Usual Care
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Columbia University
Osteoporosis, Breast Cancer
Bone Health Management for Women Diagnosed With Breast Cancer
The purpose of this study is to test the feasibility of the study protocol. The study protocol was designed to evaluate questions - "Do educational materials improve dual x-ray absorptiometry (DXA) screening rates for women…
- Trial name
- NCT02484131
- Testing
- Educational materials/mail, Educational materials/participant choice
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University of British Columbia
Breast Neoplasms, Recurrence
Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention
The main purpose of our study is to assess the effect of a lifestyle intervention combining weight control, diet and physical activity on the risk of recurrences among breast cancer patients with non-metastatic tumours in terms…
- Trial name
- PREDICOP (NCT02035631)
- Testing
- Diet, Physical activity, Minimal diet intervention
- Where
- 5 sites in Spain
- Volunteers
- 2,000 people
- Sponsor
- Institut Català d'Oncologia
Breast Cancer
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Anastrozole Tablet under fasted conditions.
- Trial name
- NCT01155102
- Testing
- Anastrozole
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Cortisol Overproduction
Salivary Cortisol as Stress Marker in Newborns Subjected to Double Weighing With Physiological Body Weight
According to scientific revisions, salivary cortisol is a valid method for measuring adrenocortical activity in newborns because it is non-invasive in fact the measurement of salivary cortisol has been used as a stress marker in…
- Trial name
- NCT03830437
- Testing
- Evaluation of newborn stress, Evaluation of body weight trend
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
Cancer Survivor, Central Obesity
Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer
This randomized phase II trial studies how well exercise intervention works in targeting adiposity and inflammation with movement to improve prognosis in stage I-III breast cancer survivors.
- Conditions
- Cancer Survivor, Central Obesity, Estrogen Receptor Positive, Postmenopausal
- Trial name
- NCT03091842
- Testing
- Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Southern California
Breast Cancer
Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance
Endocrine therapy is an established treatment for hormone receptor-positive breast cancer, but can cause significant side effects with deterioration in quality of life.
- Trial name
- NCT04864405
- Testing
- Morning administration of endocrine therapy, Evening administration of endocrine therapy
- Where
- 2 sites in Canada
- Volunteers
- 245 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and methotrexate, work in different ways to stop the growth of…
- Trial name
- NCT00616122
- Testing
- cyclophosphamide, methotrexate, sunitinib malate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2 (HER2)-negative stage III-IV breast…
- Conditions
- HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT02157051
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
Breast Cancers
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer…
- Trial name
- OPTIMAL-BC (NCT07095023)
- Testing
- Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
- Where
- 9 sites in China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses.
- Conditions
- HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
- Trial name
- HER2 (NCT05650879)
- Testing
- ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 198 people
- Sponsor
- Enliven Therapeutics
Breast Cancer
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
All patients (with Stages 0-II breast cancer) will receive an accelerated three week regimen of prone whole breast radiotherapy.
- Trial name
- NCT01000662
- Testing
- Daily Radiation Therapy, Weekly Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 412 people
- Sponsor
- NYU Langone Health
Breast Cancer
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
The propose of this prospective study focuses on the role of [18F]FES PET imaging in patients with breast cancer who might receive or are receiving hormone therapy.
- Trial name
- breast (NCT03544762)
- Testing
- 18F-FES PET
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore…
- Trial name
- NCT05891561
- Testing
- Pertuzumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer, Brain Metastasis
Brain Metastasis Development Mechanism in BCBM Patients
This study is the experimental study for brain metastasis development mechanism in patients with breast cancer with brain metastasis
- Trial name
- NCT06330870
- Testing
- WGS/TME evaluation
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
- Trial name
- Catalyst (NCT05383170)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 6 people
- Sponsor
- Cytovation AS
Cancer, Breast, Health Care Utilization
Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care
This mixed methods study evaluates the effectiveness of an organizational intervention to enhance implementation of strategies to increase breast cancer survivorship symptom and risk management.
- Trial name
- NCT05400941
- Testing
- Practice Led Intervention
- Where
- United States
- Volunteers
- 910 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Breast Neoplasms, Neoplasm Metastasis
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer.
- Trial name
- NCT00319254
- Testing
- SKI-606 (Bosutinib)
- Where
- 15 sites in United States, Australia and 6 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor…
- Trial name
- monarcHER (NCT02675231)
- Testing
- Abemaciclib, Trastuzumab, Fulvestrant
- Where
- 93 sites in United States, Argentina and 12 more
- Volunteers
- 237 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Breast Cancer
AT13387 in Adults With Refractory Solid Tumors
Background: The experimental drug AT13387 has been shown to have some anticancer effects against tumor cells by blocking a protein that affects other proteins inside certain cancer cells, and helps to prevent the cancer cells…
- Trial name
- NCT01246102
- Testing
- AT13387
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.